HealthEquity (NASDAQ:HQY) Bolsa

HEALTHEQUITY INC

HealthEquity

HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.

Oil,Field,Site,,In,The,Evening,,Oil,Pumps,Are,Running

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ATER

OABI

ONVO

Las acciones en EE. UU. suben a mitad de jornada, lideradas por un crecimiento en energía. El Dow sube 200 pts y el petróleo repunta.

Wall Street en alza: Dow sube 200 puntos mientras el petróleo y el oro se mantienen firmes

Pre-Market Outlook

FIVE

STNE

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este miércoles: SIG, WSM, HQY, STNE y FIVE.

5 acciones en el foco este miércoles: SIG, WSM, HQY, STNE y FIVE

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

GETY

SGMO

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este martes: IHS, HQY, GETY, SGMO y STNE.

5 acciones en el foco este martes: IHS, HQY, GETY, SGMO y STNE

HealthEquity Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Barrington Research raised HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) price target from $112 to $125. Barrington Research analyst Alexander Paris maintained an Outperform rating. HealthEquity shares closed at $113.6 on Wednesday. <a href="https://www.benzinga.com/quote/HQY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho boosted the price target for Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) from $100 to $115. Mizuho analyst David Bellinger maintained a Neutral rating. Five Below shares closed at $121.24 on Wednesday. <a href="https://www.benzinga.com/quote/FIVE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho raised Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) price target from $124 to $130. Mizuho analyst Vijay Rakesh maintained an Outperform rating. Micron shares closed at $103.25 on Wednesday. <a href="https://www.benzinga.com/quote/MU/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised the price target for Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) from $80 to $96. Morgan Stanley analyst Simeon Gutman maintained an Equal-Weight rating. Dollar Tree Enterprise shares closed at $88.62 on Wednesday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities increased the price target for Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) from $86 to $103. B of A Securities analyst Omar Dessouky maintained a Buy rating. Roblox shares closed at $91.05 on Wednesday. <a href="https://www.benzinga.com/quote/RBLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs raised Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) price target from $107 to $122. Goldman Sachs analyst Kate McShane maintained a Buy rating. Five Below shares settled at $121.24 on Wednesday. <a href="https://www.benzinga.com/quote/FIVE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co increased BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) price target from $134 to $145. HC Wainwright &amp; Co. analyst Robert Burns maintained a Buy rating. BioNTech shares closed at $111.14 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson raised Sprinklr, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) price target from $8 to $9. DA Davidson analyst Clark Wright maintained a Neutral rating. Sprinklr shares closed at $9.06 on Wednesday.  <a href="https://www.benzinga.com/quote/CXM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut the price target for Victoria&#8217;s Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) from $23 to $22. Barclays analyst Adrienne Yih maintained an Overweight rating. Victoria&#8217;s Secret shares settled at $20.47 on Wednesday. <a href="https://www.benzinga.com/quote/VSCO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank raised The Williams Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) price target from $52 to $59. Scotiabank analyst Brandon Bingham maintained a Sector Perform rating. Williams shares closed at $60.10 on Wednesday. <a href="https://www.benzinga.com/quote/WMB/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying CRWD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/MU/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="554" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05154557/image-73-1024x554.png" alt="" class="wp-image-940314" style="width:603px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05154557/image-73-1024x554.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05154557/image-73-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05154557/image-73-768x415.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05154557/image-73.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45790405/top-2-defensive-stocks-that-are-ticking-portfolio-bombs">Top 2 Defensive Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Price Target

Analyst Ratings

BNTX

DLTR

RBLX

VSCO

Micron To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday

Barrington Research analyst Alexander Paris maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Outperform and raises the price target from $112 to $125.

Barrington Research Maintains Outperform on HealthEquity, Raises Price Target to $125

Deutsche Bank analyst George Hill maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Buy and raises the price target from $98 to $115.

Deutsche Bank Maintains Buy on HealthEquity, Raises Price Target to $115

HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) posted better-than-expected first-quarter results after Tuesday&#8217;s closing bell.
HealthEquity reported quarterly earnings of 97 cents per share, which beat the consensus estimate of 88 cents. Quarterly revenue came in at $330.8 million, beating the Street estimate of $321.17 million.
"The HealthEquity team started fiscal 2026 with a strong first quarter that included record quarterly revenue, record Adjusted EBITDA and increased guidance for the year," said Scott Cutler, CEO of HealthEquity.
HealthEquity raised its fiscal 2026 adjusted EPS guidance from a range of $3.57 to $3.74 to a new range of $3.61 to $3.78, versus the $3.63 analyst estimate. The company reiterated its 2026 revenue outlook for a range of $1.28 billion to $1.3 billion, versus the $1.3 billion estimate.
HealthEquity shares gained 9.8% to $113.94 on Wednesday.
These analysts made changes to their price targets on HealthEquity following earnings announcement.
<ul class="wp-block-list">
<li>JMP Securities analyst Constantine Davides maintained HealthEquity with a Market Outperform and raised the price target from $110 to $117.</li>
<li>B of A Securities analyst Allen Lutz maintained the stock with a Buy and raised the price target from $110 to $125.</li>
<li>RBC Capital analyst Daniel Perlin maintained HealthEquity with an Outperform rating and raised the price target from $112 to $117.</li>
<li>Goldman Sachs analyst David Roman maintained HealthEquity with a Neutral and raised the price target from $94 to $104.</li>
</ul>
Considering buying HQY stock? Here&#8217;s what analysts think: 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/06/45762621/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fal">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a> </li>
</ul>
Photo via Shutterstock

HealthEquity Analysts Boost Their Forecasts After Upbeat Earnings

Goldman Sachs analyst David Roman maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Neutral and raises the price target from $94 to $104.

Goldman Sachs Maintains Neutral on HealthEquity, Raises Price Target to $104

U.S. stocks were slightly higher, with the Dow Jones index gaining around 0.1% on Wednesday.
Shares of Guidewire Software, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) rose sharply during Wednesday's session after the company reported better-than-expected third-quarter financial results. Also, multiple firms raised their respective <a href="https://www.benzinga.com/quote/GWRE/earnings">price targets on the stock</a>.
Guidewire Software reported quarterly earnings of 88 cents per share which beat the analyst consensus estimate of 47 cents per share. The company reported quarterly sales of $293.51 million which beat the analyst consensus estimate of $286.39 million.
Guidewire Software shares jumped 19.1% to $259.83 on Wednesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Ctrl Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCTR#NASDAQ">MCTR</a>) shares jumped 54% to $50.67.</li>
<li>Yext, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) gained 27.8% to $8.71 after the company raised its FY26 adjusted EPS guidance above estimates. Also, Needham reiterated a Buy rating on the stock.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) rose 22.7% to $12.58.</li>
<li>REV Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REVG#NYSE">REVG</a>) rose 16.7% to $43.45 after the company reported better-than-expected second-quarter financial results and raised its FY25 sales guidance.</li>
<li>Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) gained 15.8% to $36.05.</li>
<li>Redwire Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) rose 15.2% to $17.05 after the company announced it will advance lunar and martian manufacturing technology after receiving a NASA critical design review pass.</li>
<li>New Fortress Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) jumped 15.2% to $3.1800.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) gained 13.5% to $6.74. Navitas Semiconductor recently announced it has entered a partnership with BrightLoop for hydrogen fuel-cell charge.</li>
<li>STMicroelectronics N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) gained 11.1% to $28.50.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 10% to $670.00. Regencell Bioscience recently announced a 38-for-1 forward stock split.</li>
<li>HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) gained 9.2% to $113.30 after the company reported better-than-expected first-quarter adjusted EPS results and raised its FY26 guidance. Also, multiple firms raised their respective price targets on the stock.</li>
<li>KB Financial Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KB#NYSE">KB</a>) rose 8.6% to $79.70.</li>
<li>Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) gained 7.5% to $83.47 after the company raised its fourth-quarter guidance. Additionally, Rosenblatt raised its price target on the stock from $94 to $105.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) rose 7.5% to $3.7997.</li>
</ul>
Now Read This<a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen">: </a>
<ul class="wp-block-list">
<li><a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a></li>
</ul>
Photo via Shutterstock

Movers

APLD

GWRE

LITE

MCTR

NVTS

REVG

YEXT

ZLAB

Guidewire Software Posts Upbeat Q3 Results, Joins Yext, REV Group And Other Big Stocks Moving Higher On Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>UBS raised Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) price target from $120 to $128. UBS analyst Michael Lasser maintained a Buy rating. Dollar General shares closed at $112.62 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/DG/analyst-ratings">view this stock</a>.</li>
<li>Mizuho boosted the price target for Viper Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) from $54 to $55. Mizuho analyst William Janela maintained an Outperform rating. Viper Energy shares closed at $41.41 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/VNOM/analyst-ratings">view this stock</a>.</li>
<li>Goldman Sachs raised XP Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XP#NASDAQ">XP</a>) price target from $17 to $23. Goldman Sachs analyst Tito Labarta upgraded the stock from Neutral to Buy. XP shares closed at $19.33 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/XP/analyst-ratings">view this stock</a>.</li>
<li>UBS raised the price target for Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) from $16 to $18. UBS analyst David Vogt maintained a Neutral rating. Hewlett Packard Enterprise shares closed at $17.68 on Tuesday. <a href="https://www.benzinga.com/quote/HPE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital increased the price target for Ferguson Enterprises Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) from $189 to $231. RBC Capital analyst Mike Dahl maintained an Outperform rating. Ferguson shares closed at $211.53 on Tuesday. <a href="https://www.benzinga.com/quote/FERG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised Guidewire Software, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) price target from $135 to $160. B of A Securities analyst Brad Sills maintained an Underperform rating. Guidewire shares settled at $218.13 on Tuesday. <a href="https://www.benzinga.com/quote/GWRE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo increased Johnson Controls International plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) price target from $100 to $130. Wells Fargo analyst Joe O&#8217;Dea maintained an Overweight rating. Johnson Controls shares closed at $101.18 on Tuesday. <a href="https://www.benzinga.com/quote/JCI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JMP Securities raised HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) price target from $110 to $117. JMP Securities analyst Constantine Davides maintained a Market Outperform rating. HealthEquity shares closed at $103.76 on Tuesday.  <a href="https://www.benzinga.com/quote/hqy/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo increased the price target for Signet Jewelers Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) from $70 to $75. Wells Fargo analyst Ike Boruchow maintained an Equal-Weight rating. Signet shares settled at $75.24 on Tuesday. <a href="https://www.benzinga.com/quote/sig/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) price target from $83 to $90. B of A Securities analyst Erika Najarian maintained a Buy rating. Wells Fargo shares closed at $75.65 on Tuesday. <a href="https://www.benzinga.com/quote/wfc/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying WFC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/WFC/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04110010/image-52-1024x583.png" alt="" class="wp-image-938410" style="width:686px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04110010/image-52-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04110010/image-52-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04110010/image-52-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04110010/image-52.png 1118w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/06/45762621/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fal">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a></li>
</ul>
Photo via Shutterstock

FERG

VNOM

Wells Fargo To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday

WIIM

HealthEquity shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results and raised its FY26 guidance. Also, multiple firms raised their respective price targets on the stock.

RBC Capital analyst Daniel Perlin maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Outperform and raises the price target from $112 to $117.

RBC Capital Maintains Outperform on HealthEquity, Raises Price Target to $117

10 analysts have shared their evaluations of HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $110.9, with a high estimate of $125.00 and a low estimate of $94.00. Observing a downward trend, the current average is 1.47% lower than the prior average price target of $112.56. 
<img src="https://www.benzinga.com/files/images/story/2025/1749045618_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of HealthEquity among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$117.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$112.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$94.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>C. Gregory Peters</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to HealthEquity. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of HealthEquity compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of HealthEquity's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into HealthEquity's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HQY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on HealthEquity analyst ratings.</a>
<h2>All You Need to Know About HealthEquity</h2>
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
<h3>Financial Milestones: HealthEquity's Journey</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: HealthEquity's remarkable performance in 3M is evident. As of 31 January, 2025, the company achieved an impressive revenue growth rate of 18.84%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: HealthEquity's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.46%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): HealthEquity's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.24%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): HealthEquity's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.76%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: HealthEquity's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.52.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: HealthEquity Through The Eyes Of 10 Analysts

B of A Securities analyst Allen Lutz maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Buy and raises the price target from $110 to $125.

B of A Securities Maintains Buy on HealthEquity, Raises Price Target to $125

JMP Securities analyst Constantine Davides maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Market Outperform and raises the price target from $110 to $117.

JMP Securities Maintains Market Outperform on HealthEquity, Raises Price Target to $117

HealthEquity's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NYSE">HQY</a>) short percent of float has fallen 6.83% since its last report. The company recently reported that it has 5.82 million shares sold short, which is 7.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.82 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>HealthEquity Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749042030_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for HealthEquity has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing HealthEquity's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, HealthEquity's peer group average for short interest as a percentage of float is 4.09%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About HealthEquity?

HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) released its first-quarter results after Tuesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/06/g45757436/healthequity-reports-first-quarter-ended-april-30-2025-financial-results">details from the report. </a>
The Details: HealthEquity reported quarterly earnings of 97 cents per share, which beat the consensus estimate of 88 cents. Quarterly revenue came in at $330.8 million, beating the Street estimate of $321.17 million.
Read Next: <a href="https://www.benzinga.com/news/space/25/06/45724938/space-stocks-weekly-countdown-rocketlab-gets-analyst-love-while-virgin-galactic-slides-into-june?utm_source=articleShare">Space Stocks Weekly Countdown: RocketLab Gets Analyst Love While Virgin Galactic Slides Into June</a>
The company reported: 
<ul class="wp-block-list">
<li>9.9 million HSAs, an increase of 9% compared to the first quarter of FY25.</li>
<li>Total HSA Assets of $31.3 billion, an increase of 15% compared to the first quarter of FY25.</li>
<li>17.1 million Total Accounts, including both HSAs and complementary CDBs, an increase of 7% compared to first quarter FY25.</li>
</ul>
&#8220;The HealthEquity team started fiscal 2026 with a strong first quarter that included record quarterly revenue, record Adjusted EBITDA and increased guidance for the year,&#8221; said Scott Cutler, CEO of HealthEquity.
&#8220;We enhanced our member-first secure mobile experience to strengthen the security of our members&#8217; $31 billion of HSA Assets, increase member resources, and reduce costs.&#8221;
Outlook:&nbsp;HealthEquity raised its fiscal 2026 adjusted EPS guidance from a range of $3.57 to $3.74&nbsp;to&nbsp;a new range of $3.61 to $3.78, versus the&nbsp;$3.63&nbsp;analyst estimate. The company reiterated its 2026 revenue outlook for a range of&nbsp;$1.28 billion to $1.3 billion, versus the $1.3 billion estimate.
HQY Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Health Equity stock was up 5.01% at $108.96 in Tuesday's extended trading.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/social-media/25/06/45749596/the-viral-student-loan-solution-people-cant-stop-talking-about?utm_source=articleShare">The Viral Student Loan Solution People Can&#8217;t Stop Talking About</a></li>
</ul>
Image: Shutterstock

Health Care

After-Hours Center

HealthEquity Shares Trade Higher After Better-Than-Expected Q1 Report: Here's Why

HealthEquity shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results and raised its FY26 guidance.

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) raises FY2026 Adj EPS guidance from $3.57-$3.74 to $3.61-$3.78 vs $3.63 analyst estimate. Raises FY2026 sales outlook from $1.28 billion-$1.30 billion to $1.28 billion-$1.30 billion vs $1.30 billion estimate.

Guidance

HealthEquity Raises FY2026 Adj EPS Guidance from $3.57-$3.74 to $3.61-$3.78 vs $3.63 Est; Raises FY2026 Sales Guidance of $1.28B-$1.30B vs $1.30B Est

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) reported quarterly earnings of $0.97 per share which beat the analyst consensus estimate of $0.88 by 10.23 percent. This is a 21.25 percent increase over earnings of $0.80 per share from the same period last year. The company reported quarterly sales of $330.80 million which beat the analyst consensus estimate of $321.17 million by 3.00 percent. This is a 15.02 percent increase over sales of $287.60 million the same period last year.

Earnings Beats

HealthEquity Q1 Adj. EPS $0.97 Beats $0.88 Estimate, Sales $330.80M Beat $321.17M Estimate

<h3>Companies Reporting Before The Bell</h3>
• NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) is likely to report quarterly loss at $0.22 per share on revenue of $1.71 billion. 
• National Energy Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) is projected to report earnings for its first quarter. 
• Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) is projected to report quarterly earnings at $0.77 per share on revenue of $570.27 million. 
• Citi Trends (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRN#NASDAQ">CTRN</a>) is expected to report quarterly loss at $0.26 per share on revenue of $193.28 million. 
• Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) is likely to report quarterly earnings at $2.29 per share on revenue of $7.45 billion. 
• Signet Jewelers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) is estimated to report quarterly earnings at $1.27 per share on revenue of $1.54 billion. 
• Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) is estimated to report quarterly earnings at $1.46 per share on revenue of $10.25 billion. 
• Donaldson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DCI#NYSE">DCI</a>) is likely to report quarterly earnings at $0.96 per share on revenue of $960.74 million. 
<h3>Companies Reporting After The Bell</h3>
• Yext (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) is estimated to report quarterly earnings at $0.14 per share on revenue of $113.64 million. 
• Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) is likely to report quarterly earnings at $0.42 per share on revenue of $279.91 million. 
• Sportsman's Warehouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWH#NASDAQ">SPWH</a>) is expected to report quarterly loss at $0.47 per share on revenue of $238.25 million. 
• Mama's Creations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMA#NASDAQ">MAMA</a>) is projected to report quarterly earnings at $0.02 per share on revenue of $32.74 million. 
• CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is estimated to report quarterly earnings at $0.96 per share on revenue of $1.11 billion. 
• Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) is estimated to report earnings for its first quarter. 
• Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) is expected to report quarterly earnings at $0.50 per share on revenue of $7.92 billion. 
• HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) is projected to report quarterly earnings at $0.89 per share on revenue of $320.41 million. 
• Asana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) is projected to report quarterly earnings at $0.02 per share on revenue of $185.47 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASAN

BASE

CRWD

CTRN

MAMA

NESR

OLLI

SPWH

Earnings Scheduled For June 3, 2025

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-06-03. Here's what investors need to know before the announcement.
Analysts estimate that HealthEquity will report an earnings per share (EPS) of $0.89. 
The announcement from HealthEquity is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
In the previous earnings release, the company missed EPS by $0.03, leading to a 17.07% drop in the share price the following trading session.
Here's a look at HealthEquity's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2025</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.72</td>
<td>0.72</td>
<td>0.70</td>
<td>0.66</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.69</td>
<td>0.78</td>
<td>0.86</td>
<td>0.80</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-17.0%</td>
<td>-6.0%</td>
<td>5.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1748872883_0.png" alt="eps graph" />
<h3>Performance of HealthEquity Shares</h3>
Shares of HealthEquity were trading at $100.61 as of May 30. Over the last 52-week period, shares are up 20.34%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Perspectives on HealthEquity</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding HealthEquity.
With 8 analyst ratings, HealthEquity has a consensus rating of Outperform. The average one-year price target is $108.38, indicating a potential 7.72% upside.
<h3>Peer Ratings Comparison</h3>
The below comparison of the analyst ratings and average 1-year price targets of Alignment Healthcare, Progyny and Molina Healthcare, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Alignment Healthcare, with an average 1-year price target of $19.75, suggesting a potential 80.37% downside.</li>
<li>Analysts currently favor an Buy trajectory for Progyny, with an average 1-year price target of $24.5, suggesting a potential 75.65% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Molina Healthcare, with an average 1-year price target of $387.17, suggesting a potential 284.82% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for Alignment Healthcare, Progyny and Molina Healthcare, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>HealthEquity</td>
<td>Outperform</td>
<td>18.84%</td>
<td>$189.04M</td>
<td>1.24%</td>
</tr>
<tr>
<td>Alignment Healthcare</td>
<td>Buy</td>
<td>47.46%</td>
<td>$106.03M</td>
<td>-8.76%</td>
</tr>
<tr>
<td>Progyny</td>
<td>Buy</td>
<td>16.53%</td>
<td>$75.80M</td>
<td>3.39%</td>
</tr>
<tr>
<td>Molina Healthcare</td>
<td>Outperform</td>
<td>12.24%</td>
<td>$1.28B</td>
<td>6.77%</td>
</tr>
</tbody>
</table>

Key Takeaway:
HealthEquity ranks first in revenue growth among its peers. It has the highest gross profit margin. HealthEquity's return on equity is the lowest among its peers.
<h3>All You Need to Know About HealthEquity</h3>
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
<h3>HealthEquity: Delving into Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining HealthEquity's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 18.84% as of 31 January, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: HealthEquity's net margin excels beyond industry benchmarks, reaching 8.46%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): HealthEquity's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.24%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.76%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: HealthEquity's debt-to-equity ratio is below the industry average at 0.52, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/HQY/earnings">To track all earnings releases for HealthEquity visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: HealthEquity's Earnings Preview

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) has outperformed the market over the past 10 years by 3.51% on an annualized basis producing an average annual return of 14.02%. Currently, HealthEquity has a market capitalization of $8.48 billion. 
Buying $100 In HQY: If an investor had bought $100 of HQY stock 10 years ago, it would be worth $369.17 today based on a price of $97.90 for HQY at the time of writing.
<h3>HealthEquity's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748013320_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Legal

Press Releases

If You Have Suffered Losses in HealthEquity, Inc. (NASDAQ: HQY) You Are Encouraged to Contact The Rosen Law Firm About Your Rights

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HealthEquity, Inc. - HQY

HealthEquity Announces First Quarter Earnings Release Date Presentations at Investor Conferences

Rosen Law Firm Encourages HealthEquity, Inc. Investors to Inquire About Securities Class Action Investigation - HQY

Financing

HealthEquity Community Foundation Awards $35,000 in New Grants

HealthEquity Reports First Quarter Ended April 30, 2025 Financial Results

Alignment Healthcare, Inc. - Common Stock

Alignment Healthcare

Clover Health Investments, Corp. - Class A Common stock

Clover Health Investments

Centene

Elevance Health

Humana

Molina Healthcare

NeueHealth

Progyny

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group

Barrington Research

Deutsche Bank

Goldman Sachs

RBC Capital

B of A Securities

Comments

HealthEquity

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL